MegaQuinone AND Myomax explained
Take 2 capsules daily with a meal, or as directed by your healthcare practitioner.
Benefits of MyoMax
- mitochondria’s ATP production can increase by 40 – 50%
- helps improve aerobic capacity from cellular level
The good news is that it appears that Vitamin K2 increases cardiac output by improving mitochondrial function. A study conducted at the University of North Texas found that only 8 weeks of high dose supplementation with vitamin K2 (MK-7) was associated with a 12% increase in maximal cardiac output in athletes who utilize aerobic training.
Vitamin K2-7 has shown to lower the risk of vascular damage. Vitamin K2-7 activates the so called matrix GLA protein (MGP). MGP prevents calcium from depositing in vessel walls and joint spaces.
The body needs vitamin K2-7 to take free calcium from the blood, the deposits from the arteries and joint spaces and sends it to the bones. Therefore it improves cardiovascular health and bone health.
Please check out the “Research” section to read about the latest findings on vitamin K2-7
TANAKA H, SEALS DR. Endurance exercise performance in Masters athletes:age-associated changes and underlying physiological mechanisms. J Physiol. 2008;586(1):55-63. MCFARLIN BK, HENNING AL, VENABLE AS. Oral Consumption of Vitamin K2 for 8 Weeks Associated with Increased Maximal Cardiac Output During Exercise. Altern Ther Health Med. 2017;23(4):26-32. VOS M, ESPOSITO G, EDIRISINGHE JN, ET AL. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science. 2012;336(6086):1306-10. KULKARNI VK, UPASE DP, DOUND YA, ET AL. The effect of vitamin K2-7 in peripheral neuropathy due to Vitamin B12 deficiency and/or diabetes mellitus: A Preliminary Study. Indian Practitioner. 2013;66(10):625-629. GEORGIEVA E, IVANOVA D, ZHELEV Z, ET AL. Mitochondrial dysfunction and redox imbalances as a diagnostic marker of “free radical diseases”. Anticancer Res. 2017;37(10):5373-5381. SEYFRIED TN. Cancer as a mitochondrial metabolic disease. Front Cell Dev Bio. 2015;3(43):1-12. GANGULY G, CHAKRABARTI S, CHATTERJEE U, SASO L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer’s disease and Parkinson’s disease. Drug Des Devel Ther. 2017;11:797-810. GAO F, YANG J, WANG J, ET AL. Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications. 2017;8:527. SURESHBABU A, BHANDARI V. Targeting mitochondrial dysfunction in lung diseases: emphasis on mitophagy. Front Physiol. 2013;4:Article 384. PARADIES G, PARADIES V, RUGGIERO FM, ET AL. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(39):14205-14218. AUGER C, ALHASAWI A, CONTAVADOO M, ET AL. Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders. Front Cell Dev Bio. 2015;3:40.